Breaking News Instant updates and real-time market news.

REGN

Regeneron

$371.68

-4.11 (-1.09%)

, TEVA

Teva

$42.96

-1.32 (-2.98%)

07:03
10/17/16
10/17
07:03
10/17/16
07:03

Teva, Regeneron plan to design pivotol Phase 3 study in chronic low back pain

REGN

Regeneron

$371.68

-4.11 (-1.09%)

TEVA

Teva

$42.96

-1.32 (-2.98%)

  • 30

    Oct

  • 04

    Nov

  • 06

    Nov

  • 15

    Nov

  • 29

    Mar

REGN Regeneron
$371.68

-4.11 (-1.09%)

09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.
10/13/16
BTIG
10/13/16
NO CHANGE
Target $18
BTIG
Buy
Ocular deal with Regeneron has favorable terms, says BTIG
BTIG analyst Ling Wang believes Ocular Therapeutix's (OCUL) strategic collaboration with Regeneron (REGN) comes with favorable deal terms. The back-end loaded structure brings the potential for large upside, Wang tells investors in a research note. In addition, the partnership provides external validation for Ocular's platform technology, Wang adds. The analyst reiterates a Buy rating on the shares with an $18 price target
TEVA Teva
$42.96

-1.32 (-2.98%)

10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.
10/07/16
LEER
10/07/16
NO CHANGE
Target $57
LEER
Outperform
Teva price target lowered to $57 from $61 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
10/12/16
LEER
10/12/16
NO CHANGE
Target $70
LEER
Outperform
Neurocrine recent selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.

TODAY'S FREE FLY STORIES

AJRD

Aerojet Rocketdyne

$32.30

0.55 (1.73%)

07:52
09/22/17
09/22
07:52
09/22/17
07:52
Upgrade
Aerojet Rocketdyne rating change  »

Aerojet Rocketdyne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$47.15

-0.13 (-0.27%)

07:50
09/22/17
09/22
07:50
09/22/17
07:50
Conference/Events
Applied Materials to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

07:50
09/22/17
09/22
07:50
09/22/17
07:50
General news
Fedspeak returned from the blackout period »

Fedspeak returned from…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:49
09/22/17
09/22
07:49
09/22/17
07:49
Hot Stocks
Phillips 66 Partners to sell $750M of Series A preferred units »

Phillips 66 Partners LP…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Hot Stocks
Phillips 66 Partners announces $2.4B acquisition of interests from Phillips 66 »

Phillips 66 Partners…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$21.60

-0.25 (-1.14%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Recommendations
Versartis analyst commentary  »

Cantor still sees 55%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXEL

Exelixis

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Downgrade
Exelixis rating change  »

Exelixis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners »

Phillips 66 Partners to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$24.66

-1.13 (-4.38%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Technical Analysis
Technical View: U.S. Steel falls in early trading, analyst action »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

07:45
09/22/17
09/22
07:45
09/22/17
07:45
Recommendations
Zimmer Biomet analyst commentary  »

Value investors should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:45
09/22/17
09/22
07:45
09/22/17
07:45
General news
N.Y. FX Outlook »

N.Y. FX Outlook: The…

BABA

Alibaba

$177.39

-0.56 (-0.31%)

, TCEHY

Tencent

$44.15

-0.15 (-0.34%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Periodicals
Alibaba, Tencent look towards emerging markets in mobile-payments race, WSJ says »

Chinese companies Alibaba…

BABA

Alibaba

$177.39

-0.56 (-0.31%)

TCEHY

Tencent

$44.15

-0.15 (-0.34%)

AAPL

Apple

$153.39

-2.68 (-1.72%)

GOOG

Alphabet

$932.45

0.87 (0.09%)

GOOGL

Alphabet Class A

$947.55

0.01 (0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

SPR

Spirit AeroSystems

$78.90

0.76 (0.97%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Conference/Events
Spirit AeroSystems to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

AERI

Aerie Pharmaceuticals

$51.45

-1.95 (-3.65%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Recommendations
Aerie Pharmaceuticals analyst commentary  »

Aerie pullback on AdComm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Feb

CSCO

Cisco

$32.70

0.1 (0.31%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Conference/Events
Cisco management to meet with Deutsche Bank »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

EFX

Equifax

$98.25

2.25 (2.34%)

07:41
09/22/17
09/22
07:41
09/22/17
07:41
Technical Analysis
Technical View: Equifax trades higher, analyst action »

Shares are back well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AA

Alcoa

$46.25

-1.25 (-2.63%)

07:41
09/22/17
09/22
07:41
09/22/17
07:41
Downgrade
Alcoa rating change  »

Alcoa downgraded to Hold,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMX

CarMax

$68.84

0.17 (0.25%)

07:40
09/22/17
09/22
07:40
09/22/17
07:40
Earnings
CarMax reports Q2 EPS 98c, consensus 95c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

SYK

Stryker

$140.67

-2.04 (-1.43%)

, ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

07:40
09/22/17
09/22
07:40
09/22/17
07:40
Recommendations
Stryker, Zimmer Biomet analyst commentary  »

Growth investors should…

SYK

Stryker

$140.67

-2.04 (-1.43%)

ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

SAVE

Spirit Airlines

$34.01

1.31 (4.01%)

07:39
09/22/17
09/22
07:39
09/22/17
07:39
Conference/Events
Spirit Airlines to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

IBM

IBM

$145.26

-0.62 (-0.43%)

, WBA

Walgreens Boots Alliance

$78.20

-0.64 (-0.81%)

07:39
09/22/17
09/22
07:39
09/22/17
07:39
Hot Stocks
IBM announces new agreement with Walgreens to deploy IBM retail analytics »

IBM (IBM) announced a new…

IBM

IBM

$145.26

-0.62 (-0.43%)

WBA

Walgreens Boots Alliance

$78.20

-0.64 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 23

    Sep

  • 22

    Oct

  • 25

    Oct

  • 15

    Nov

07:38
09/22/17
09/22
07:38
09/22/17
07:38
Conference/Events
Federal Reserve Bank of Dallas President participates in a conference »

Dallas Federal Reserve…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.